Skip to main content
. 2017 Feb 28;23(8):1489–1496. doi: 10.3748/wjg.v23.i8.1489

Figure 1.

Figure 1

Scatter diagram of the study patients. Of these 138 subjects, 84 (60.9%) had quiescent disease and 54 (39.1%) had active disease. The overall median infliximab trough level (IFX-TL) value was 0.941 μg/mL. In total, 91 patients were antibodies to infliximab (ATI) negative (65.9%) and 47 patients were ATI positive (34.1%), with an overall median ATI value of 8.846 (IQR 7.719-16.727) AU/mL.